Also found in: Dictionary, Thesaurus, Wikipedia.
Related to carvedilol: Ramipril


a beta-adrenergic blocking agent used in treatment of hypertension and as an adjunct in treatment of congestive heart failure; administered orally.


Apo-Carvedilol (CA), Coreg, Dom-Carvedilol (CA), Eucardic (UK)

carvedilol phosphate

Coreg CR, Novo-Carvedilol (CA), PHL-Carvedilol (CA), PMS-Carvedilol (CA)

Pharmacologic class: Beta-adrenergic blocker (nonselective)

Therapeutic class: Antihypertensive

Pregnancy risk category C


Blocks stimulation of cardiac beta1-adrenergic receptor sites and pulmonary beta2-adrenergic receptor sites. Shows intrinsic sympathomimetic activity, causing slowing of heart rate, decreased myocardial excitability, reduced cardiac output, and decreased renin release from kidney.


Capsules (extended-release): 10 mg, 20 mg, 40 mg, 80 mg

Tablets: 3.125 mg, 6.25 mg, 12.5 mg, 25 mg

Indications and dosages


Adults: Initially, 6.25 mg P.O. b.i.d. (Coreg). May be increased q 7 to 14 days to a maximum dosage of 25 mg b.i.d. Or, 20 mg P.O. daily (Coreg CR). If tolerated, using standing systolic pressure about 1 hour after dosing, maintain dosage of Coreg CR for 7 to 14 days; then increase to 40 mg once daily if needed based on trough systolic standing blood pressure. Maintain this dosage for 7 to 14 days and adjust to 80 mg once daily if tolerated and needed. Total daily dose of Coreg CR shouldn't exceed 80 mg.

Heart failure caused by ischemia or cardiomyopathy

Adults: Initially, 3.125 mg P.O. b.i.d. (Coreg) for 2 weeks. May increase to 6.25 mg b.i.d. Dosage may be doubled q 2 weeks as tolerated, not to exceed 25 mg b.i.d. in patients weighing less than 85 kg (187 lb) or 50 mg b.i.d. in patients weighing more than 85 kg. Or, 10 mg P.O. daily (Coreg CR) for 2 weeks. If tolerated, increase dosage to 20 mg, 40 mg, and 80 mg over successive intervals of at least 2 weeks.

Left ventricular dysfunction following myocardial infarction

Adults: Initially, 6.25 mg P.O. b.i.d. (Coreg); increase after 3 to 10 days to 12.5 mg b.i.d. (based on tolerability), then increase to target dosage of 25 mg b.i.d. A lower starting dose (3.125 mg b.i.d.) or slower titration may be used if clinically indicated. Or, 20 mg P.O. once daily (Coreg CR); increase after 3 to 10 days to 40 mg daily (based on tolerability), then increase to target dose of 80 mg daily. A lower starting dose may be used (10 mg daily) or the rate of up titration may be slowed if clinically indicated.

Off-label uses

• Angina pectoris

• Idiopathic cardiomyopathy


• Hypersensitivity to drug

• Uncompensated heart failure

• Pulmonary edema

• Cardiogenic shock

• Bradycardia or heart block

• Severe hepatic impairment

• Bronchial asthma, bronchospasm


Use cautiously in:

• renal or hepatic impairment, pulmonary disease, diabetes mellitus, hypoglycemia, thyrotoxicosis, peripheral vascular disease, hypotension, respiratory depression

• elderly patients

• pregnant or breastfeeding patients

• children.


• Ensure that patient is hemodynamically stable and fluid retention has been minimized before starting therapy.

• Give immediate-release form with food to slow absorption and minimize orthostatic hypotension.

• Give extended-release form in the morning with food and instruct patient to swallow capsule whole.

• For patients who can't swallow capsules whole, carefully open capsules and sprinkle contents on applesauce; have patient swallow contents immediately without chewing. Don't use warm applesauce; doing so could affect the modified-release properties of this formulation.

• When drug is used to treat heart failure, check apical pulse before administering. If it's below 60 beats/minute, withhold dosage and contact prescriber.

• When drug is used for hypertension, check standing systolic pressure about 1 hour after dosing for use as a guide for patient tolerance.

• Be aware that addition of diuretic may cause additive effects and may worsen orthostatic hypotension.

• Know that full antihypertensive effect takes 7 to 14 days.

Don't withdraw drug abruptly, because this may lead to withdrawal phenomenon (angina exacerbation, myocardial infarction, ventricular arrhythmias, and even death).

Adverse reactions

CNS: dizziness, fatigue, anxiety, depression, insomnia, memory loss, nightmares, headache, pain

CV: orthostatic hypotension, peripheral vasoconstriction, angina pectoris, chest pain, hypertension, bradycardia, heart failure, atrioventricular block

EENT: blurred or abnormal vision, dry eyes, stuffy nose, rhinitis, sinusitis, pharyngitis

GI: nausea, diarrhea, constipation

GU: urinary tract infection, hematuria, albuminuria, decreased libido, erectile dysfunction, renal dysfunction

Hematologic: bleeding, purpura, thrombocytopenia

Metabolic: hypovolemia, hypervolemia, hyperglycemia, hyponatremia, hyperuricemia, glycosuria, gout, hypoglycemia

Musculoskeletal: arthralgia, back pain, muscle cramps

Respiratory: wheezing, upper respiratory tract infection, dyspnea, bronchitis, bronchospasm, pulmonary edema

Skin: pruritus, rash

Other: weight gain, lupuslike syndrome, viral infection, anaphylaxis


Drug-drug. Antihypertensives: additive hypotension

Calcium channel blockers, general anesthetics, I.V. phenytoin: additive myocardial depression

Cimetidine: increased carvedilol toxicity

Clonidine: increased hypotension and bradycardia, exaggerated withdrawal phenomenon

Digoxin: additive bradycardia

Dobutamine, dopamine: decrease in beneficial cardiovascular effects

Insulin, oral hypoglycemics: altered efficacy of these drugs

MAO inhibitors: hypertension

Nonsteroidal anti-inflammatory drugs: decreased antihypertensive action

Rifampin, thyroid preparations: decreased carvedilol efficacy

Theophyllines: reduced theophylline elimination, antagonistic effect that decreases theophylline or carteolol efficacy

Drug-diagnostic tests. Antinuclear antibodies: increased titers

Blood urea nitrogen, glucose, lipoproteins, potassium, triglycerides, uric acid: increased levels

Drug-food. Any food: delayed drug absorption

Drug-behaviors. Acute alcohol ingestion: additive hypotension

Patient monitoring

• Watch for signs and symptoms of hypersensitivity reaction.

• Assess baseline CBC and kidney and liver function test results.

• Monitor vital signs (especially blood pressure), ECG, and exercise tolerance. Drug may alter cardiac output and cause ineffective airway clearance.

• Weigh patient daily and measure fluid intake and output to detect fluid retention.

• Measure blood glucose regularly if patient has diabetes mellitus. Drug may mask signs and symptoms of hypoglycemia.

Patient teaching

• Instruct patient to take drug with food exactly as prescribed.

• Tell patient to take extended-release capsule in the morning with food, to swallow capsule whole, and not to chew, crush, or divide its contents.

• Instruct patient who can't swallow capsule whole to carefully open capsule, sprinkle contents on cool or cold applesauce, and swallow contents immediately without chewing. Tell patient not to store mixture for future use.

Caution patient not to stop taking drug abruptly, because serious reactions may result.

• Advise patient to move slowly when sitting up or standing, to avoid dizziness or light-headedness from sudden blood pressure drop.

• Caution patient to avoid driving and other hazardous activities until he knows how drug affects concentration and alertness.

• Inform male patient that drug may cause erectile dysfunction. Advise him to discuss this issue with prescriber.

• Advise patient to use soft-bristled toothbrush and electric razor to avoid gum and skin injury.

• As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs, tests, foods, and behaviors mentioned above.


An antihypertensive and antianginal agent, also used in congestive heart failure.


(kär-vā′dĭ-lôl′, -lōl′ -vĕd′ĭ-)
A beta-blocker drug, C24H26N2O4, used especially to treat congestive heart failure and hypertension.


A drug used in the treatment of HEART FAILURE and ANGINA PECTORIS. A brand name is Eucardic.
References in periodicals archive ?
The researchers found that the primary end point of prevention of a ≥10 percent reduction in LVEF at six months occurred in 14.5 and 13.5 percent of patients in the carvedilol and placebo groups, respectively (P = 1.0).
Carvedilol. In our case, the potassium level rose to 5.6 mEq/L when the patient (with type III renal insufficiency) was on carvedilol 12.5 mg bid but it normalized (though at the upper limit of normal--5 mEq/L) when the dose of carvedilol was reduced to 6.25 mg bid.
Antiarrhythmic evaluation of studied drugs was assessed by recording [Ca.sup.2+] transients at baseline (perfusate only), 3 min after 1 [micro]M adrenaline incubation and if recorded transients exhibited [Ca.sup.2+] abnormalities (Figures 3 and 4), 5 min after 0.25 [micro]M carvedilol (Sigma) or 10 [micro]M flecainide (Sigma) perfusion at the presence of 1 [micro]M adrenaline.
Changes in sleep pattern were noticed only due to changing the dosage or posology of Carvedilol (CVD) and Nitroglicerine (NTG) (Table III).
The student inadvertently tested carvedilol's ant-icancer effect rather than its ability to promote cancer, finding that carvedilol surprisingly showed some protective effects against skin cancer.
The rats were randomly divided into five groups (10 rats per group): sham surgery control group, bile duct ligation (BDL) model group, low-dose carvedilol treatment group (0.1 mg x [kg.sup.-1] x [d.sup.-1], CAR-L), medium-dose carvedilol treatment group (1 mg x [kg.sup.-1] x [d.sup.-1], CAR-M), and high-dose carvedilol treatment group (10 mg x [kg.sup.-1] x [d.sup.-1], CAR-H).
The objective of the present study was to evaluate the effects of carvedilol and a regimen of supervised aerobic exercise training on quality of life and other clinical, echocardiographic, and biochemical variables in a group of client-owned dogs with CMVD.
Three of the drugs--bisoprolol, carvedilol, and metoprolol succinate--showed similar reductions relative to placebo in all-cause mortality, hospitalization for heart failure, and tolerability.
For example, one very exciting finding of our study is that Carvedilol, already approved for treatment of hypertension, may immediately become a promising drug for the treatment of Alzheimer's as well."
James DiNicolantonio, Pharm.D., and his colleagues conducted a systematic review and meta-analysis comparing outcomes between clinical trial subjects with systolic HF or AMI receiving carvedilol and those receiving [beta.sub.1]-selective BBs (specifically atenolol, metoprolol, bisoprolol, and nebivolol) (Am.
The researchers remind us that in addition to being a beta-nonselective BB and an alpha, blocker, carvedilol may have unique vasodilating, antioxidant, and antiarrhythmic effects.
After 10 days of placebo run-in period, they were randomized within the same group as cross-over design to one month carvedilol 25 mg and one month nebivolol 5 mg regimen given once daily in the morning.